Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Association of patient-reported outcomes and ovarian cancer recurrence

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

Kargo, A. S., Jensen, P. T., Lindemann, K., Hjøllund, N. H., Liposits, G. I., Raaschou-Jensen, N., Knudsen, B. M., Möller, S., Hansen, D. G., & Steffensen, K. D. (2021). Association of patient-reported outcomes and ovarian cancer recurrence. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(9), 1248-1259. https://doi.org/10.1136/ijgc-2021-002550

CBE

MLA

Vancouver

Author

Kargo, Anette Stolberg ; Jensen, Pernille Tine ; Lindemann, Kristina ; Hjøllund, Niels Henrik ; Liposits, Gabor Istvan ; Raaschou-Jensen, Nicoline ; Knudsen, Bettina Mølri ; Möller, Sören ; Hansen, Dorte Gilså ; Steffensen, Karina Dahl. / Association of patient-reported outcomes and ovarian cancer recurrence. I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2021 ; Bind 31, Nr. 9. s. 1248-1259.

Bibtex

@article{04705c3023404352bb59e08f6ace1159,
title = "Association of patient-reported outcomes and ovarian cancer recurrence",
abstract = "BACKGROUND: The vast majority of patients with advanced ovarian cancer experience disease recurrence after primary treatment.OBJECTIVE: To explore the diagnostic accuracy of repeated measurement of patient-reported outcomes and quality-of-life scores in relation to ovarian cancer recurrence.METHODS: Patients with ovarian cancer were recruited to the PROMova study by the end of their primary treatment at eight centers in Denmark. The purpose of the PROMova study was to explore the applicability of repeated use of patient-reported outcomes, which consisted of the European Organization for Research and Treatment of Cancer generic questionnaire and the ovarian specific questionnaire. The patient-reported outcomes were completed 3, 6, 9, 12, and 15 months after enrollment or until recurrence. The 3-month interval between completions was the period in which recurrence was assessed. Imaging and the biomarker CA125 were used as reference modality for recurrence. Mixed effects logistic regression was used to investigate the association between mean patient-reported outcome scores and recurrence. Receiver operating curves were used to establish cut-off scores. The diagnostic accuracy of patient-reported outcomes, including sensitivity, specificity, and positive and negative predictive values was estimated based on the Youden index. For combined scales, diagnostic accuracy was investigated based on multivariate analysis.RESULTS: The analysis included 196 patients with an overall recurrence rate of 50.5% and an overall mean time to recurrence of 302 days. With imaging as reference, patients with recurrence reported significantly lower global health, worse physical functioning, and more abdominal symptoms preceding recurrence. With CA125 as reference, global health, physical and emotional functioning were impaired. Despite the worsening of a number of symptoms prior to recurrence whichever reference modality was applied, the patient-reported outcome scores did not provide adequate diagnostic accuracy.CONCLUSION: Repeated use of patient-reported outcomes during surveillance of ovarian cancer was not of diagnostic value. Future efforts should be directed at improving the administration of patient-reported outcomes as well as exploring the potential of using these outcomes as an indicator of clinical relevance.",
keywords = "Carcinoma, Ovarian Epithelial/diagnosis, Female, Humans, Neoplasm Recurrence, Local/diagnosis, Patient Reported Outcome Measures, medical oncology, ovarian neoplasms, quality of life (pro)/palliative care",
author = "Kargo, {Anette Stolberg} and Jensen, {Pernille Tine} and Kristina Lindemann and Hj{\o}llund, {Niels Henrik} and Liposits, {Gabor Istvan} and Nicoline Raaschou-Jensen and Knudsen, {Bettina M{\o}lri} and S{\"o}ren M{\"o}ller and Hansen, {Dorte Gils{\aa}} and Steffensen, {Karina Dahl}",
note = "{\textcopyright} IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2021",
month = sep,
day = "1",
doi = "10.1136/ijgc-2021-002550",
language = "English",
volume = "31",
pages = "1248--1259",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams & Wilkins",
number = "9",

}

RIS

TY - JOUR

T1 - Association of patient-reported outcomes and ovarian cancer recurrence

AU - Kargo, Anette Stolberg

AU - Jensen, Pernille Tine

AU - Lindemann, Kristina

AU - Hjøllund, Niels Henrik

AU - Liposits, Gabor Istvan

AU - Raaschou-Jensen, Nicoline

AU - Knudsen, Bettina Mølri

AU - Möller, Sören

AU - Hansen, Dorte Gilså

AU - Steffensen, Karina Dahl

N1 - © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - BACKGROUND: The vast majority of patients with advanced ovarian cancer experience disease recurrence after primary treatment.OBJECTIVE: To explore the diagnostic accuracy of repeated measurement of patient-reported outcomes and quality-of-life scores in relation to ovarian cancer recurrence.METHODS: Patients with ovarian cancer were recruited to the PROMova study by the end of their primary treatment at eight centers in Denmark. The purpose of the PROMova study was to explore the applicability of repeated use of patient-reported outcomes, which consisted of the European Organization for Research and Treatment of Cancer generic questionnaire and the ovarian specific questionnaire. The patient-reported outcomes were completed 3, 6, 9, 12, and 15 months after enrollment or until recurrence. The 3-month interval between completions was the period in which recurrence was assessed. Imaging and the biomarker CA125 were used as reference modality for recurrence. Mixed effects logistic regression was used to investigate the association between mean patient-reported outcome scores and recurrence. Receiver operating curves were used to establish cut-off scores. The diagnostic accuracy of patient-reported outcomes, including sensitivity, specificity, and positive and negative predictive values was estimated based on the Youden index. For combined scales, diagnostic accuracy was investigated based on multivariate analysis.RESULTS: The analysis included 196 patients with an overall recurrence rate of 50.5% and an overall mean time to recurrence of 302 days. With imaging as reference, patients with recurrence reported significantly lower global health, worse physical functioning, and more abdominal symptoms preceding recurrence. With CA125 as reference, global health, physical and emotional functioning were impaired. Despite the worsening of a number of symptoms prior to recurrence whichever reference modality was applied, the patient-reported outcome scores did not provide adequate diagnostic accuracy.CONCLUSION: Repeated use of patient-reported outcomes during surveillance of ovarian cancer was not of diagnostic value. Future efforts should be directed at improving the administration of patient-reported outcomes as well as exploring the potential of using these outcomes as an indicator of clinical relevance.

AB - BACKGROUND: The vast majority of patients with advanced ovarian cancer experience disease recurrence after primary treatment.OBJECTIVE: To explore the diagnostic accuracy of repeated measurement of patient-reported outcomes and quality-of-life scores in relation to ovarian cancer recurrence.METHODS: Patients with ovarian cancer were recruited to the PROMova study by the end of their primary treatment at eight centers in Denmark. The purpose of the PROMova study was to explore the applicability of repeated use of patient-reported outcomes, which consisted of the European Organization for Research and Treatment of Cancer generic questionnaire and the ovarian specific questionnaire. The patient-reported outcomes were completed 3, 6, 9, 12, and 15 months after enrollment or until recurrence. The 3-month interval between completions was the period in which recurrence was assessed. Imaging and the biomarker CA125 were used as reference modality for recurrence. Mixed effects logistic regression was used to investigate the association between mean patient-reported outcome scores and recurrence. Receiver operating curves were used to establish cut-off scores. The diagnostic accuracy of patient-reported outcomes, including sensitivity, specificity, and positive and negative predictive values was estimated based on the Youden index. For combined scales, diagnostic accuracy was investigated based on multivariate analysis.RESULTS: The analysis included 196 patients with an overall recurrence rate of 50.5% and an overall mean time to recurrence of 302 days. With imaging as reference, patients with recurrence reported significantly lower global health, worse physical functioning, and more abdominal symptoms preceding recurrence. With CA125 as reference, global health, physical and emotional functioning were impaired. Despite the worsening of a number of symptoms prior to recurrence whichever reference modality was applied, the patient-reported outcome scores did not provide adequate diagnostic accuracy.CONCLUSION: Repeated use of patient-reported outcomes during surveillance of ovarian cancer was not of diagnostic value. Future efforts should be directed at improving the administration of patient-reported outcomes as well as exploring the potential of using these outcomes as an indicator of clinical relevance.

KW - Carcinoma, Ovarian Epithelial/diagnosis

KW - Female

KW - Humans

KW - Neoplasm Recurrence, Local/diagnosis

KW - Patient Reported Outcome Measures

KW - medical oncology

KW - ovarian neoplasms

KW - quality of life (pro)/palliative care

UR - http://www.scopus.com/inward/record.url?scp=85108567815&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2021-002550

DO - 10.1136/ijgc-2021-002550

M3 - Journal article

C2 - 34489355

VL - 31

SP - 1248

EP - 1259

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -

ID: 74085312